在重组胶原蛋白的江湖中，丸美用十二年完成了从"跟随者"到"赶超者"的角色转化。 在第五届重组胶原蛋白科学论坛上，《FBe a u t y未来迹》发现，丸美生物对重组胶原蛋白行业 的贡献可以概括为两点： 其一是在技术领域的里程碑式突破 。五年前，丸美推出了重组全人源化胶原蛋白，实现与人 体 同 源 、 高 活 性 与 高 稳 定 性 ， 打 破 国 外 抗 衰 成 分 垄 断 ， 标 志 着 中 国 抗 衰 成 分 正 式 进 入 " 4G 时 代"。 而在2 0 2 5年，丸美技术升级至毕赤酵母改造体系，重组双胶原蛋白实现五大一致（序列、活 性、结构、羟基化、纤维化），达到"与人一模一样的胶原蛋白"，并获得IFSCC首个中国技术 创新奖。 其二是成为"标准制定者"，发挥引领重组胶原蛋白高质量健康发展的产业价值 。目前，丸美 主导制定、工信部批准立项的《重组可溶性胶原》行业标准已箭在弦上，公司发布《重组胶原 蛋白国际院士专家共识》，提出序列、结构、活性"三一致"及五大高质量标准，不遗余力推动 行业有序发展。 而且值得注意的是，丸美一路走来，并非"弯道超车"，而是"开山辟路"。 " 只有中国成分的全面崛起，才能开 ...

Investment Rating - Investment rating for the social services industry is "Positive" (maintained) [1] Core Insights - The report highlights a robust growth in the tourism sector during the May Day holiday, with a significant increase in cross-regional travel demand and a notable rise in high-end hotel bookings [14][20] - The report indicates a strong performance in the trendy toy market, with a 39% year-on-year increase in the number of offline stores and a 17% increase in average store efficiency [27][28] - The Chinese restaurant market, particularly the Chinese noodle shop segment, is projected to grow significantly, with a compound annual growth rate of 11.6% from 2024 to 2029 [34] - The service robotics market is expected to grow rapidly, with a projected market size of 97 billion by 2028, driven by advancements in AI technology and increasing demand for efficient service [44][48] - The domestic beauty market is seeing a trend towards high-end products, with significant upgrades in product formulations and technology [50][51] Summary by Sections 1. Travel and Tourism - The May Day holiday is expected to see a peak in travel demand, with an estimated daily cross-regional flow of over 270 million people [14] - Domestic flight ticket prices have decreased, leading to a 29% increase in search interest among price-sensitive university students [18] - The trend of travel consumption is shifting towards lower-tier cities, with a 25% increase in tourism heat compared to higher-tier cities [18] 2. Trendy Toys - As of March 2025, the number of offline trendy toy stores reached 3,645, marking a 39% year-on-year growth [27] - The average store efficiency for trendy toy stores increased by 17% year-on-year, with significant variations among brands [28] 3. Restaurant Industry - The Chinese noodle shop market is projected to reach a total transaction value of 495.6 billion by 2029, with a compound annual growth rate of 11.6% from 2024 to 2029 [34] - The company "Encounter Small Noodles" achieved a revenue of 1.154 billion in 2024, reflecting a 44.2% year-on-year growth [37] 4. Service Robotics - The service robotics market in China is expected to grow from 30 billion in 2023 to 97 billion by 2028, with a compound annual growth rate of 26.5% [44][48] - The hotel sector is the largest segment within the service robotics market, projected to reach 36 billion by 2028 [45] 5. Beauty Industry - The beauty market is experiencing a shift towards high-end products, with significant upgrades in formulations and technology [50] - The "Giant Biological" brand launched an upgraded collagen stick, which has seen a 32% year-on-year growth in sales [51]

2 0 2 5年，中国彩妆市场的比拼已经卷到n e x t l e v e l。 一方面，极度饱和的市场正在面临结构性汰换。自去年以来已经有一大批新锐彩妆品牌在流量 和价格内卷中倒下。另一方面在功效热潮中，当彩妆产品的功能价值向前大步快跑，设计与审 美也成为"向上卷"的重要方向。 这个4月，丸美生物旗下专业彩妆Pa ssi o n a l Lo v e r恋火（后文简称PL）用新品复刻出一整个 海岛度假场景，为市场带来了一个功能性与美学性"双赢"的答案。 《FBe a u t y未来迹》发现，全新「海岛限定」系列可谓PL的"集大成之作"——延续限定产品策 略的思路，功能上做到极致的好用，设计上更是具有实打实的美感，所有消费者拿到产品的一 瞬间都为之一振。 正如丸美生物董事会主席兼CEO孙怀庆和PL品牌主理人孙云起所说： 过去几年PL的成功在于 对"易用且好用" "以触手可及的价格享受奢侈品品质"的坚持。而对于彩妆而言，"向上卷"的正 确方向还有"美智生产力"，只有源源不断地为市场为消费者提供对美的向往和美的欣赏，才能 够真正赢得消费者 。 丸美生物董事会主席兼CEO孙怀庆 " 限 定 " 二 字 对 彩 妆 ...

Investment Rating - Investment rating: Positive (maintained) [1] Core Insights - The report highlights the growth potential in the medical beauty and cosmetics sectors, driven by innovative products and changing consumer preferences towards self-care and emotional consumption [6][7][36][50] - The medical beauty segment is expected to benefit from the approval of new products, particularly in the recombinant collagen market, which is gaining traction as a substitute for animal-derived collagen [6][31][49] - The cosmetics industry is witnessing a rise in domestic brands, with a focus on high-quality products and emotional connections with consumers, suggesting a shift towards "self-care" trends [7][36][50] Summary by Sections Market Review - The beauty and personal care index rose by 3.41% in March, outperforming the broader market [15][18] - Notable stock performances in the medical beauty sector included Jinbo Biological (+32.2%), Furuier Medical Technology (+22.8%), and Kedi-B (+9.5%) [19] - In the cosmetics sector, Shangmei Co. (+31.8%), Maogeping (+31.6%), and Runben Co. (+16.4%) led the gains [25] Medical Beauty - Jinbo Biological received approval for its recombinant type III human collagen gel, marking a significant advancement in the medical beauty field [6][31] - The product offers dual benefits of filling and repairing, positioning Jinbo as a leader in the recombinant collagen market [31][33] - The report emphasizes the importance of differentiated strategies in the recombinant collagen industry, including technological advancements and diverse product offerings [33] Cosmetics - The report identifies the "self-care" trend as a key driver in the cosmetics market, with consumers increasingly seeking products that enhance their emotional well-being [7][36] - It suggests focusing on domestic brands that are adapting to market trends and consumer preferences, particularly in high-growth segments [37][50] - The report highlights the rise of high-end domestic brands, with Maogeping being a notable example, leveraging its unique brand identity and product quality [42][50] Investment Recommendations - The report recommends focusing on leading domestic beauty brands that are expected to gain market share, including Maogeping, Shangmei Co., and Runben Co. [49][50][53] - It suggests that the medical beauty sector will see growth driven by new product launches and the increasing acceptance of domestic brands [49][51] - The report anticipates that the emotional consumption trend will continue to shape the cosmetics market, creating opportunities for brands that can connect with consumers on a deeper level [50][51]

丸美生物 2025041720250416 摘要 丸美生物在产品研发方面有哪些优势？ 丸美生物在产品研发方面具有显著优势。公司长期专注于眼霜和抗衰老产品， 并深入消费者心智。在研发上，公司早期就开始布局弹性胶原蛋白、弹性纤维 蛋白等领域，并近几年推出重组胶原蛋白。这种重组胶原蛋白与人体胶原蛋白 氨基酸序列 100%一致，包括一型和三型嵌合双螺旋结构，在安全性、活性和 功效上表现优异。 去年（2024 年）4 月，公司进行了重组胶原蛋白 2.0 升级， 并推出了小金针次抛系列产品，该系列获得了良好的市场反响。此外，公司还 布局了高浓度胜肽、视黄醇、裂褶多糖、植物提取物等优质原料，并发布了烟 草育种组织化妆品专利。这些创新材料为公司未来推出新产品提供了坚实基础， 有望继续吸引消费者喜爱。 目前丸美生物的渠道策略如何影响其业绩？ 丸美生物近年来通过优化渠道策略显著提升业绩。过去公司的核心问题在于未 能匹配当前消费者需求，但通过调整营销方式释放出了产品势能。例如，小红 笔作为四年前的产品，在去年（2024 年）实现了 100%以上增长，这表明新 的营销策略有效推动销售。今年（2025 年）一季度，小红笔、小金针两款主 ...

Core Insights - The trend of "makeup and medical integration" is gaining significant attention in the beauty industry, with major brands accelerating their entry into the medical aesthetics sector [1][5] - The medical aesthetics market is viewed as a new growth driver, despite the current early-stage development of the interaction between beauty and medical aesthetics [1][5] Industry Developments - Leading beauty brands are actively investing in the medical aesthetics sector, with various strategies such as investing in upstream research and launching related medical brands or products [2][3] - Notable actions include Shiseido's announcement of its first medical beauty brand in China, L'Oréal's strategic partnership with Tru Diagnostic, and Estée Lauder's collaboration with Jia Hui Medical in Shanghai [2][3] Domestic Market Movements - Domestic brands like Marubi and Gu Yu are also making significant moves in the medical aesthetics space, with Marubi investing in a medical materials R&D company and Gu Yu collaborating with a research institute to explore innovative medical products [3] - Other domestic brands such as Pechoin, Aimeike, and Furuida are also accelerating the integration of medical aesthetics and beauty [3] Market Potential - The medical aesthetics market in China is expected to reach a scale of 381.6 billion to 410.8 billion yuan by 2025, making it a crucial growth area globally [5][6] - The overlap between beauty and medical aesthetics consumer groups is driving beauty companies to enter the medical aesthetics market [5][6] Competitive Landscape - Differentiation is key for brands looking to penetrate the medical aesthetics market, as the sector faces high regulatory barriers and technical challenges [6][7] - The current market primarily features Class II medical devices, with brands focusing on consumer needs during the perioperative period of medical aesthetics [6] Industry Trends - The integration of beauty and medical aesthetics is reshaping the competitive landscape, with both domestic and international brands needing to adapt to a market transitioning from rapid growth to stable development [7] - The industry is undergoing a significant reshuffle, emphasizing the need for brands to balance consumer demand with the rigor of medical standards [7]

Investment Rating - The report maintains a "Buy" rating for the cosmetics and medical beauty industry, highlighting the potential for domestic brands to gain market share and improve competitive dynamics [4]. Core Insights - The domestic beauty market is expected to see an optimization in competitive dynamics, driven by a rise in domestic consumption and a retreat of international brands due to increasing geopolitical uncertainties [9][10]. - The cosmetics and medical beauty sector outperformed the market during the period from April 3 to April 11, 2025, with the Shenwan Beauty Care Index declining by 2.5%, which is better than the Shenwan A Index's decline of 1.9 percentage points [5][6]. Summary by Sections Industry Performance - The cosmetics and medical beauty sector showed resilience, with key indices performing better than the overall market, indicating a positive trend for domestic brands [5][6]. - The report notes that the retail sales growth for cosmetics in January and February 2025 was 4.4%, outperforming the overall retail sales growth of 4.0% [23]. Market Trends - According to Euromonitor data, the market for domestic skincare and makeup brands is on the rise, with significant improvements in market share for brands like Proya and Natural Hall, which have entered the top ten in market share [9][35]. - The report anticipates that domestic brands will continue to benefit from the trend of rising domestic consumption, especially as international brands face challenges [10][35]. Company Performance Forecasts - For Q1 2025, several companies are expected to report positive growth: - Up Beauty Co. is projected to see a revenue and net profit increase of 10% year-on-year [11]. - Marubi is expected to achieve a revenue increase of 40% and a net profit increase of 35% [11]. - Proya is forecasted to have a revenue increase of 8% and a net profit increase of 10% [11]. - The report highlights that companies like Giant Biological and Mao Geping are also expected to see significant growth, with revenue and net profit both projected to increase by 40% and 25% respectively [11]. Investment Recommendations - The report recommends focusing on companies with strong brand matrices and high growth potential, such as Up Beauty Co., Proya, and Marubi, which are well-positioned to leverage the e-commerce boom [14]. - It also suggests keeping an eye on companies like Shanghai Jahwa and Betaini, which are expected to perform well in the upcoming quarters [14]. Industry Dynamics - The report discusses the entry of four prominent researchers into Proya, indicating a strong focus on technological innovation and talent development within the company [26]. - The competitive landscape in the medical beauty sector is evolving, with new products and innovations expected to drive growth and market share for companies like Jinbo Biological and Huaxi Biological [29][30].

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Viewpoints - The report emphasizes the ongoing impact of tariff shocks and suggests focusing on high-quality retail channels and differentiated consumer brands that cater to domestic demand [4][22] - The report highlights the transformation of traditional retail, with Yonghui Supermarket leading the way in adapting to a consumer-centric retail era [4][22] - The rise of domestic brands and the recovery of consumer demand are seen as inevitable trends, with recommendations to focus on quality retail channels and differentiated brands [4][22] Summary by Sections Retail Market Review - The retail industry index rose by 2.88% during the week of April 7 to April 11, outperforming the Shanghai Composite Index, which fell by 3.11% [6][13] - The supermarket sector showed the largest increase, with a weekly rise of 13.54% [14][17] - Notable individual stock performances included Guofang Group (+61.1%), Eurasia Group (+26.3%), and Nanning Department Store (+22.4%) [19][20] Industry Dynamics - Yonghui Supermarket has opened a "green channel" for domestic manufacturers affected by export restrictions, receiving over 100 cooperation requests from various sectors [4][22] - The report discusses the approval of a new collagen product by Jinbo Bio, which is expected to strengthen its leading position in the medical beauty sector [4][23] Investment Recommendations - Investment focus areas include: - Traditional retail: Highlighting companies like Yonghui Supermarket and Aiyingshi that are adapting to consumer trends [7][27] - Gold and jewelry: Recommendations for brands like Laopu Gold and Chaohongji that possess differentiated product capabilities [7][28] - Cosmetics: Emphasizing domestic brands such as Maogeping and Shangmei that are expanding into high-potential segments [7][28] - Medical aesthetics: Focusing on companies like Aimeike and Kedi that are positioned to benefit from the recovery in medical beauty consumption [7][28] Company-Specific Insights - Laopu Gold reported a revenue of 8.506 billion yuan (+167.5%) and a net profit of 1.473 billion yuan (+253.9%) for FY2024, indicating strong growth potential [29] - Yonghui Supermarket's revenue for the first three quarters of 2024 was 54.549 billion yuan (-12.1%), with a net loss of 78 million yuan, but it is undergoing significant transformation [32] - Jinbo Bio's new collagen product is expected to provide both immediate filling effects and stimulate collagen regeneration, enhancing its competitive edge in the market [23][24]

Core Insights - The beauty and medical aesthetics sectors are increasingly merging, with significant interest from both international giants and local startups, indicating a strong growth trend in this area [1][5][31] - L'Oréal is a leading player in this trend, having made substantial investments and strategic moves to integrate beauty and medical aesthetics [2][10][17] Group 1: Industry Trends - Since 2024, there has been an unusual enthusiasm among beauty companies to enter the medical aesthetics business, with both high-end and budget brands participating [1] - The merger of beauty and medical aesthetics is not a new concept, but it is gaining momentum, with companies like L'Oréal leading the charge [1][5] - The retail sales of cosmetics in China fell by 1.1% in 2024, while the total retail sales of consumer goods grew by 3.5%, highlighting the need for beauty brands to innovate and find new growth avenues [5] Group 2: Company Developments - In 2023, L'Oréal rebranded its active health cosmetics division to the skin science beauty division and launched its core brand, SkinCeuticals, in 2024 [2] - Estee Lauder's Clinique launched a series of medical device products, while Shiseido is set to introduce its first medical beauty brand in China [3] - Domestic brands like Shiseido and Up Beauty are also making strides in the medical aesthetics space, with new product launches and business developments [4] Group 3: Strategic Initiatives - L'Oréal's beauty tech transformation strategy, initiated in 2018, focuses on integrating technology into beauty and medical aesthetics, with significant investments in digital R&D [6][8] - The company has established a comprehensive network for integrating beauty and medical aesthetics, including investments in high-end medical beauty chains and partnerships with biotech firms [17][18] - L'Oréal's SkinCeuticals brand has seen a 9.8% year-on-year growth, reaching €7.03 billion in revenue, making it the fastest-growing segment of the group [10] Group 4: Market Dynamics - The merging of beauty and medical aesthetics allows brands to create a closed-loop product offering, enhancing customer loyalty and repeat purchases [22] - The shift towards medical aesthetics is seen as a necessary strategy to avoid intense competition in traditional beauty markets [19][20] - However, the differing operational models and regulatory requirements between beauty and medical aesthetics present new challenges for companies [24][30]

Group 1: Macro and Strategy Insights - The manufacturing PMI recorded a slight increase to 50.5% in March, with production and new orders indices rising marginally [8] - The report emphasizes the importance of pricing long-term positive factors during market adjustments, suggesting that the market is transitioning to a more pragmatic stance [9] - The bond market is expected to perform well due to the unexpected tariffs, with a shift towards a steeper yield curve anticipated [16] Group 2: Financial and Real Estate Sector - The banking sector is expected to maintain stable performance with better-than-expected interest margins, focusing on high-dividend stocks [19] - The real estate sector is under pressure but is expected to show signs of bottoming out, with the importance of stabilizing the sector increasing amid trade tensions [23] - Construction investment is anticipated to recover, driven by improvements in manufacturing PMI and external shocks [25] Group 3: Materials and Energy Sector - Oil prices have declined due to OPEC's production increase and tariff impacts, but shale oil costs provide strong support for prices [26] - The chemical sector is responding to U.S. tariffs with a focus on self-sufficiency, highlighting the importance of domestic production trends [31] - The coal market is expected to stabilize as demand increases with the arrival of the peak season, supported by fiscal policies [36] Group 4: Consumer and Healthcare Sector - The pharmaceutical industry remains optimistic despite potential tariff impacts, particularly in the innovative drug supply chain [24] - The agricultural sector is under scrutiny due to unexpected tariff policies, with a focus on investment opportunities in various sub-sectors [11] Group 5: Technology and AI Sector - The AI industry is experiencing significant breakthroughs, with a focus on domestic computing power and the emergence of physical AI as a new frontier [4] - The report highlights the potential for AI applications in low-digital penetration sectors such as finance, education, and healthcare [4]